3,4-Methylenedioxy-N-hydroxyamphetamine: Difference between revisions
Appearance
Content deleted Content added
IznoRepeat (talk | contribs) m →External links: remove template per TFD; gen fixes |
m task, replaced: : → : |
||
(8 intermediate revisions by 8 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Psychedelic amphetamine}} |
|||
{{DISPLAYTITLE:3,4-Methylenedioxy-''N''-hydroxyamphetamine}} |
{{DISPLAYTITLE:3,4-Methylenedioxy-''N''-hydroxyamphetamine}} |
||
{{Infobox drug |
|||
{{Drugbox |
|||
| drug_name = 3,4-Methylenedioxy-''N''-hydroxyamphetamine |
| drug_name = 3,4-Methylenedioxy-''N''-hydroxyamphetamine |
||
| IUPAC_name = 1-(1,3-Benzodioxol-5-yl)-''N''-hydroxypropan-2-amine |
| IUPAC_name = 1-(1,3-Benzodioxol-5-yl)-''N''-hydroxypropan-2-amine |
||
| image = |
| image = MDOH_structure.svg |
||
| width = 200px |
| width = 200px |
||
Line 13: | Line 14: | ||
| legal_DE = Anlage I |
| legal_DE = Anlage I |
||
| legal_US = Schedule I |
| legal_US = Schedule I |
||
| legal_UN = P I |
|||
| routes_of_administration = |
| routes_of_administration = |
||
Line 30: | Line 32: | ||
| PubChem = 98528 |
| PubChem = 98528 |
||
| DrugBank = |
| DrugBank = |
||
| KEGG = C22807 |
|||
| ChemSpiderID = 88979 |
| ChemSpiderID = 88979 |
||
Line 37: | Line 40: | ||
}} |
}} |
||
'''3,4-Methylenedioxy-''N''-hydroxyamphetamine''' ('''MDOH''', '''MDH''', '''N-hydroxytenamphetamine''') is an [[entactogen]], [[psychedelic drug|psychedelic]], and [[stimulant]] of the [[substituted phenethylamine|phenethylamine]] and [[substituted amphetamine|amphetamine]] [[chemical class]]es. It is the ''N''-[[hydroxyl|hydroxy]] [[ |
'''3,4-Methylenedioxy-''N''-hydroxyamphetamine''' ('''MDOH''', '''MDH''', '''N-hydroxytenamphetamine''') is an [[entactogen]], [[psychedelic drug|psychedelic]], and [[stimulant]] of the [[substituted phenethylamine|phenethylamine]] and [[substituted amphetamine|amphetamine]] [[chemical class]]es.<ref name="de_Boer_2004">{{cite journal | vauthors = de Boer D, Bosman I | title = A new trend in drugs-of-abuse; the 2C-series of phenethylamine designer drugs | journal = Pharmacy World & Science | volume = 26 | issue = 2 | pages = 110–113 | date = April 2004 | pmid = 15085947 | doi = 10.1023/b:phar.0000018600.03664.36 }}</ref> It is the ''N''-[[hydroxyl|hydroxy]] [[Homologous series|homologue]] of [[3,4-Methylenedioxyamphetamine|MDA]], and the ''N''-[[desmethyl]] homologue of [[methylenedioxyhydroxymethamphetamine|MDHMA]]. MDOH was first [[Organic synthesis|synthesized]] and [[assay]]ed by [[Alexander Shulgin]].<ref name = "CitePiHKAL">{{CitePiHKAL|name-list-style = vanc }}</ref> In his book ''[[PiHKAL]]'' (''Phenethylamines i Have Known And Loved''), Shulgin listed the dosage range as 100–160 mg, and the duration as approximately 3–6 hours.<ref name = "CitePiHKAL" /> He describes MDOH as being very psychedelic and producing increased pleasure in beauty and nature.<ref name = "CitePiHKAL" /> He also mentioned several negative side effects also seen with [[MDMA]] ("Ecstasy") such as difficulty urinating and internal dryness.<ref name = "CitePiHKAL" /> |
||
== References == |
== References == |
||
Line 52: | Line 55: | ||
{{Phenethylamines}} |
{{Phenethylamines}} |
||
{{DEFAULTSORT:Methylenedioxy-N-hydroxyamphetamine, 3,4-}} |
{{DEFAULTSORT:Methylenedioxy-N-hydroxyamphetamine, 3, 4-}} |
||
[[Category:Substituted amphetamines]] |
[[Category:Substituted amphetamines]] |
||
[[Category:Designer drugs]] |
[[Category:Designer drugs]] |
||
Line 59: | Line 62: | ||
[[Category:Entactogens and empathogens]] |
[[Category:Entactogens and empathogens]] |
||
[[Category:Hydroxylamines]] |
[[Category:Hydroxylamines]] |
||
[[Category:Human drug metabolites]] |
|||
Latest revision as of 03:41, 10 May 2024
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C10H13NO3 |
Molar mass | 195.218 g·mol−1 |
3D model (JSmol) | |
|
3,4-Methylenedioxy-N-hydroxyamphetamine (MDOH, MDH, N-hydroxytenamphetamine) is an entactogen, psychedelic, and stimulant of the phenethylamine and amphetamine chemical classes.[1] It is the N-hydroxy homologue of MDA, and the N-desmethyl homologue of MDHMA. MDOH was first synthesized and assayed by Alexander Shulgin.[2] In his book PiHKAL (Phenethylamines i Have Known And Loved), Shulgin listed the dosage range as 100–160 mg, and the duration as approximately 3–6 hours.[2] He describes MDOH as being very psychedelic and producing increased pleasure in beauty and nature.[2] He also mentioned several negative side effects also seen with MDMA ("Ecstasy") such as difficulty urinating and internal dryness.[2]
References
[edit]- ^ de Boer D, Bosman I (April 2004). "A new trend in drugs-of-abuse; the 2C-series of phenethylamine designer drugs". Pharmacy World & Science. 26 (2): 110–113. doi:10.1023/b:phar.0000018600.03664.36. PMID 15085947.
- ^ a b c d Shulgin A, Shulgin A (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628.
External links
[edit]